rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Calidi Biotherapeutics, Inc.

CLDI · NYSE American

Health CareBiotechnologyNot moving yet

CLDI stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 67.6% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$1,241
Officials’ trades on record
0
Institutions holding
24 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$438KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders24-3 on the quarter
New · exited5 · 8
Reported value$89K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026114,550$19K+51,531+81.8%
HighTower Advisors, LLCunchanged · filed 5 Aug 202683,523$14K00.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 202654,274$9,227+19,472+56.0%
Independent Advisor Alliancenew · filed 12 Aug 202645,000$7,650+45,000
RS CRUM INC.added · filed 10 Aug 202643,239$7,351+2,983+7.4%
Arax Advisory Partnersunchanged · filed 10 Aug 202637,345$6,34900.0%
Private Advisor Group, LLCnew · filed 27 Jul 202630,000$5,100+30,000
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202625,509$4,33700.0%
Belpointe Asset Management LLCunchanged · filed 31 Jul 202619,921$3,38700.0%
NORTHERN TRUST CORPunchanged · filed 13 Aug 202617,758$3,01900.0%
30 Sep 2025 – 30 Jun 2026
222527Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Alan R. Stewart Company insiderDirector · last 17 Aug 20260 · 0
Andrew C. Jackson Company insiderChief Financial Officer · last 17 Aug 20261 · 0
Corazon (Corsee) D. Sanders Company insiderDirector · last 17 Aug 20260 · 0
Eric E. Poma Company insiderChief Executive Officer · last 17 Aug 20261 · 0
George Peoples Company insiderDirector · last 17 Aug 20260 · 0
James A. Schoeneck Company insiderDirector · last 17 Aug 20261 · 0
Santidrian Antonio Fernandez Company insiderChief Scientific Officer · last 17 Aug 20260 · 0
Scott Leftwich Company insiderDirector · last 17 Aug 20261 · 0
Allan Camaisa Company insiderDirector · last 12 Dec 20250 · 2
Boris Radoslavov Minev Company insiderInterim Chief Medical Officer · last 17 Jun 20240 · 0
Wendy Pizarro Campbell Company insiderChief Admin. and Legal Officer · last 17 Jun 20240 · 0
Alfonso G. Zulueta Company insiderDirector · last 21 Dec 20230 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Debt to equityFY 2025 · to 31 Dec 20250.18×
Share count trendFY 2025 · to 20 Mar 202651.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.8M

Analyst forecasts

No analyst forecasts yet.